N,N-双(2-氯乙基)氨基甲酸叔丁酯 | 118753-70-1

• 物质功能分类: 有机原料 - 含氮基化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N,N-双(2-氯乙基)氨基甲酸叔丁酯
• 中文别名: 双(2-氯乙基)氨基甲酸叔丁酯；N-BOC-N,N-二(2-氯乙基)胺；N-BOC-N,N-双(2-氯乙基)胺
• 英文名称: N-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine
• 英文别名: tert-butyl bis(2-chloroethyl)carbamate；tert-butyl N,N-bis(2-chloroethyl)carbamate；N-tert-butoxycarbonyl-bis(2-chloroethyl)amine；N-boc-bis(2-chloroethyl)amine；bis(2-chloroethyl)carbamic acid tert-butyl ester；N-(2,2'-bischloro)diethyl-N-(1,1-dimethylethoxy)carbonyl amine；N-^tbutoxycarbonyl-bis(2-chloroethyl)amine；(tert-butoxycarbonyl)bis(2-chloroethyl)amine；N-Boc-N,N-bis(2-chloroethyl)amine
• CAS: 118753-70-1
• 化学式: C₉H₁₇Cl₂NO₂
• mdl: MFCD06858679
• 分子量: 242.145
• InChiKey: FQZLNQAUUMSUHT-UHFFFAOYSA-N

物化性质

• 沸点：
  290.7±33.0 °C(Predicted)
• 密度：
  1.149±0.06 g/cm3(Predicted)
• 闪点：
  130 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2924199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存储条件：2~8℃，干燥且密封。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Boc-N,N-bis(2-chloroethyl)amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Boc-N,N-bis(2-chloroethyl)amine
CAS number: 118753-70-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H17Cl2NO2
Molecular weight: 242.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

N,N-双(2-氯乙基)氨基甲酸叔丁酯的应用

N,N-双(2-氯乙基)氨基甲酸叔丁酯可用作医药化学和有机合成的中间体。在有机合成转化中，结构中的Boc基团很容易脱除，从而得到活性的羧基基团。

合成方法

将5克（0.028摩尔）双-(2-氯乙基)-胺盐酸盐溶解于42毫升二氯甲烷中，形成悬浮液。在冰浴下，缓慢搅拌该溶液，并逐滴加入6.11克（0.028摩尔）二碳酸二叔丁酯的28毫升二氯甲烷溶液。室温搅拌反应18.5小时后，再向混合物中加入30毫升二氯甲烷。分离两相，用水进一步萃取水相中的有机成分。合并后的有机层经无水硫酸镁干燥、过滤和浓缩，最终得到N,N-双(2-氯乙基)氨基甲酸叔丁酯。

反应信息

• 作为反应物：
  描述：

  N,N-双(2-氯乙基)氨基甲酸叔丁酯 在 ammonium hydroxide 作用下， 反应 5.5h， 以94.3%的产率得到N-Boc-哌嗪
  参考文献：
  名称：

  一种N-Boc哌嗪的合成方法

  摘要：

  本发明公开了一种N‑Boc哌嗪的合成方法。该方法以二乙胺醇为起始物料，经过氯化、Boc保护、氨解环合三步合成N‑Boc哌嗪。该方法的原料易得，反应条件温和，产品的成本低，收率高，纯度高，适宜于工业化生产。

  公开号：

  CN108033931B
• 作为产物：
  描述：

  二(2-氯乙基)胺盐酸盐 生成 N,N-双(2-氯乙基)氨基甲酸叔丁酯
  参考文献：
  名称：

  WO2006/51290

  摘要：

  公开号：

文献信息

• [EN] METALLOENZYME INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE MÉTALLOENZYMES
  申请人：VPS 3 INC

  公开号：WO2018165520A1

  公开（公告）日：2018-09-13

  Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.

  提供具有HDAC6调节活性的化合物，以及通过HDAC6介导的治疗疾病、疾病或症状的方法。
• IRAK DEGRADERS AND USES THEREOF
  申请人：Kymera Therapeutics, Inc.

  公开号：US20190192668A1

  公开（公告）日：2019-06-27

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
  申请人：Bono Francoise

  公开号：US20050176722A1

  公开（公告）日：2005-08-11

  The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; p is 1 or 2; R 1 represents a halogen atom; a trifluoromethyl radical; a (C 1 -C 4 )alkyl; a (C 1 -C 4 )alkoxy; a trifluoromethoxy radical; R 2 represents a hydrogen atom or a halogen atom; R 3 represents a hydrogen atom; a group —OR 5 ; a group —CH 2 OR 5 ; a group —NR 6 R 7 ; a group —NR 8 COR 9 ; a group —NR 8 CONR 10 R 11 ; a group —CH 2 NR 12 R 13 ; a group —CH 2 NR 8 CONR 14 R 15 ; a (C 1 -C 4 )alkoxycarbonyl; a group —CONR 16 R 17 ; or else R 3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R 4 represents an aromatic group selected from: the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C 1 -C 4 )alkyl; a (C 1 -C 4 )alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.

  该发明涉及一般式(I)的取代1-哌嗪基酰基哌啶衍生物，其中：n为1或2；p为1或2；R1代表卤原子；三氟甲基基团；(C1-C4)烷基；(C1-C4)烷氧基；三氟甲氧基基团；R2代表氢原子或卤原子；R3代表氢原子；—OR5基团；—CH2OR5基团；—NR6R7基团；—NR8COR9基团；—NR8CONR10R11基团；—CH2NR12R13基团；—CH2NR8CONR14R15基团；(C1-C4)烷氧羰基；—CONR16R17基团；或者R3构成与其连接的碳原子和哌啶环的相邻碳原子之间的双键；R4代表从中选择的芳香族基：所述芳香族基未取代或者经过单取代或双取代，取代基独立选择自卤原子；(C1-C4)烷基；(C1-C4)烷氧基；三氟甲基基团；制备方法和治疗应用。
• New heteroditopic, linked macrocyclic systems derived from selectively protected N2S2-, N3O2- and N4-donor macrocycles
  作者：Jy D. Chartres、Andrew M. Groth、Leonard F. Lindoy、Mark P. Lowe、George V. Meehan

  DOI：10.1039/b004797j

  日期：——

  The use of selectively tert-butoxycarbonyl protected derivatives of 1,9-dithia-5,13-diazacyclohexadecane 1, 1,7-dithia-4,11-diazacyclotetradecane 2, 1,4,8,11-tetraazacyclotetradecane 3 and 2,5-dioxa-8,11,14-triaza-1,6(1,2)-dibenzenacyclopentadecaphane 4 has enabled the efficient synthesis of new linked heteroditopic macrocyclic systems incorporating combinations of N2S2- and N4- or N3O2-donor sites. Incorporation of two types of binding sites in the respective products makes them suitable candidates for the synthesis of a range of mixed-metal, di- and oligo-nuclear metal complexes.

  使用经过选择性叔丁氧羰基保护的1,9-二硫-5,13-二氮杂环十六烷1、1,7-二硫-4,11-二氮杂环十四烷2、1,4,8,11-四氮杂环十四烷3以及2,5-二氧-8,11,14-三氮-1,6(1,2)-二苯并环十五烷4的衍生物，实现了包括N2S2-和N4-或N3O2-供体位点组合在内的新型连结异双位点大环体系的合成。这些产物中引入两种不同类型的结合位点，使它们成为合成一系列混合金属、二核和寡核金属配合物的合适候选。
• Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
  申请人：——

  公开号：US20030229067A1

  公开（公告）日：2003-12-11

  The subject invention provides compounds having the structure: 1 wherein, R 1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NR a R b , —NR a R b , —NR a C(═O)NR a R b , —NR a C(═O)OR a , —OC(═O)NR a R b , or —NHC(═O)R a ; R 2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NR a R b , —NR a R b , —NR a C(═O)NR a R b , —NR a C(═O)OR a , —OC(═O)NR a R b , or —NHC(═O)R a , or R 1 , R 2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH 2 ) 2 OH or —CH 2 C(═O)OH; R 3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C 1 -C 15 )alkyl, (C 1 -C 15 )alkoxy, or —NR a R b ; R 4 is hydrogen or substituted or unsubstituted (C 1 -C 15 )alkyl; R 5 is —(CH 2 ) m OR 6 , —CHNOR 7 , —C(═O)NR 8 R 9 , —(CH 2 ) m C(═O)OR 10 , —(CH 2 ) k C(═O)NR 11 R 12 ; wherein R 6 is a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 3 -C 10 )cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring; R 7 is hydrogen, or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 1 -C 30 )alkylaryl; R 8 and R 9 are each independently hydrogen, or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 1 -C 30 )alkylaryl, (C 1 -C 30 )alkylamino, (C 1 -C 30 )alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, or R 8 , N, and R 9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring; R 10 is hydrogen or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 3 -C 10 )cycloalkyl, or an aryl, heteroaryl or heterocyclic ring; R 11 , N and R 12 together form a 4-8 membered heterocyclic ring; R a and R b are each independently hydrogen or alkyl; m is 0, 1, 2 or 3; and k is 1, 2 or 3, or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A 2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.

  该主题发明提供具有以下结构的化合物： 1 其中， R 1 是取代或未取代的烷基，其中取代基是羟基、二羟基、羧基、—C(═O)NR a R b 、—NR a R b 、—NR a C(═O)NR a R b 、—NR a C(═O)OR a 、—OC(═O)NR a R b 或—NHC(═O)R a ； R 2 是氢或取代或未取代的烷基，其中取代基是羟基、二羟基、羧基、—C(═O)NR a R b 、—NR a R b 、—NR a C(═O)NR a R b 、—NR a C(═O)OR a 、—OC(═O)NR a R b 或—NHC(═O)R a ，或 R 1 、R 2 和N共同形成取代哌嗪、取代氮杂环丙烷环或取代的—(CH 2 ) 2 OH或—CH 2 C(═O)OH的吡咯烷环； R 3 是取代或未取代的苯基或5-6成员杂芳环，其中取代基是卤素、羟基、氰基、(C 1 -C 15 )烷基、(C 1 -C 15 )烷氧基或—NR a R b ； R 4 是氢或取代或未取代的(C 1 -C 15 )烷基； R 5 是—(CH 2 ) m OR 6 、—CHNOR 7 、—C(═O)NR 8 R 9 、—(CH 2 ) m C(═O)OR 10 、—(CH 2) k C(═O)NR 11 R 12 ； 其中R 6 是取代或未取代的(C 1 -C 30 )烷基、(C 3 -C 10 )环烷基或芳基、杂芳基或4-8成员杂环环； R 7 是氢或取代或未取代的(C 1 -C 30 )烷基、(C 1 -C 30 )烷基芳基； R 8 和R 9 各自独立地是氢或取代或未取代的(C 1 -C 30 )烷基、(C 1 -C 30 )烷基芳基、(C 1 -C 30 )烷基氨基、(C 1 -C 30 )烷氧基或饱和或不饱和的、单环或双环的、碳环或杂环环，或 R 8 、N和R 9 共同形成取代或未取代的4-8成员杂环环； R 10 是氢或取代或未取代的(C 1 -C 30 )烷基、(C 3 -C 10 )环烷基或芳基、杂芳基或杂环环； R 11 、N和R 12 共同形成4-8成员杂环环； R a 和R b 各自独立地是氢或烷基； m为0、1、2或3；和 k为1、2或3， 或其特定对映体，或其特定互变异构体，或其药学上可接受的盐，以及一种治疗与需要此类治疗的受试者相关的A 2b 腺苷受体相关疾病的方法，包括向受试者施用该发明化合物的治疗有效量。